A personalised cancer vaccine just cleared Phase 3
Moderna and Merck's intismeran autogene is the first personalised mRNA cancer therapy to get through a Phase 3 trial. Across 1,137 people with melanoma, the 758 who received it alongside surgery and the immunotherapy pembrolizumab saw their risk of recurrence or death fall by 49%, and the risk of the cancer spreading to distant organs fall by 59%. The vaccine is built from each patient's own tumour, which is why it took this long to prove.